Skip to Main Content

An official website of the United States government

Principal Investigator
Yue Zhang
Chongqing Medical University
Position Title
About this CDAS Project
PLCO (Learn more about this study)
Project ID
Initial CDAS Request Approval
May 8, 2023
Association between antibacterial drugs and colorectal cancer risk
Colorectal cancer is a common malignancy that kills hundreds of thousands of people worldwide each year. Antimicrobial drugs, such as cephalosporins and penicillins, are a group of drugs used to treat infections and are widely used in the medical field, but their long-term use is associated with dysbiosis of the intestinal microbiota and the risk of colorectal disease. Long-term use of antimicrobial drugs has been shown to increase the risk of colorectal cancer, especially with broad-spectrum antibiotics. In addition, antimicrobial drugs affect the composition and function of the intestinal microbiota, leading to damage to the intestinal mucosal barrier, which further increases the risk of colorectal cancer.
Some studies have suggested that long-term use of antimicrobial drugs may disrupt the intestinal microbiota, leading to changes in the bacterial community and thus increasing the risk of colorectal cancer. However, the results are inconsistent across studies and may be related to differences in study design, sample size, and patient populations. Few population-based studies have prospectively assessed the risk of exposure to colorectal adenomas with colorectal cancer, and many retrospective case-control studies have methodological challenges related to selection and recall bias. The use of PLCO cancer screening data to prospectively assess the association between antimicrobial use in prescription medications and colorectal cancer risk informs clinical practice.

The aim was to investigate the relationship between self-reported antimicrobial use in prescription drugs and the risk of colorectal cancer in the PLCO cohort, to deepen understanding of the relationship between antimicrobial use and colorectal cancer risk, to inform clinical practice, and to provide insight and direction for further research to enhance understanding of colorectal cancer treatment and improve treatment outcomes.


Name :Xi-Da Chen, institution : Chongqing Medical University